News Releases | Lexicon Pharmaceuticals, Inc.

Press Releases

Title	Published Date
Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022	Feb 28, 2022
Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022	Feb 25, 2022
Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference	Jan 13, 2022
Lexicon Pharmaceuticals to Participate in the 40th Annual J.P. Morgan Healthcare Conference	Jan 04, 2022
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults with Type 2 Diabetes	Dec 30, 2021
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference	Nov 15, 2021
Lexicon’s Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data	Nov 14, 2021
New Analysis to be Presented at the American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function	Nov 09, 2021
Lexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical Update	Nov 03, 2021
Lexicon Pharmaceuticals to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 3, 2021	Oct 28, 2021